The role of cytochrome bc₁ inhibitors in future tuberculosis treatment regimens.

ABSTRACT: Tuberculosis (TB) remains the foremost cause of death from infectious diseases globally, prompting ongoing efforts to improve treatment options. This includes developing compounds with novel modes of action and identifying optimal treatment regimens that allow for treatment shortening. One promising strategy involves targeting cytochrome bc₁ oxidase in Mycobacterium tuberculosis, a key enzyme in the respiratory chain. In this study, we evaluate the potential of cytochrome bc₁ inhibitors as partner drugs in TB combination regimens. Using a relapsing mouse model, we demonstrate that these inhibitors enhance regimen sterilisation and significantly reduce the time required for effective treatment. We also propose several novel combination strategies for both multidrug-res

SUBMITTER: Aguilar-Perez C 

PROVIDER: S-EPMC12546632 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature